• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 1st February 2011

Comparing Variants of Lead and Lag Time TTO

OHE was awarded a UK Department of Health grant to further develop three aspects of health status indexes. Results of the second of these, advances in Time Trade Off methodology, are reported in this post. As reported in an earlier…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
smformbeingticked3-27-10

OHE was awarded a UK Department of Health grant to further develop three aspects of health status indexes. Results of the second of these, advances in Time Trade Off methodology, are reported in this post.

As reported in an earlier post,  OHE was awarded a Policy Research Programme grant by the Department of Health that focuses on three aspects of health status indexes.  The second of these is a study on Time Trade Off (TTO) methodology, focusing on Lead and Lag Time TTO (LT-TTO). TTO is crucial because it helps translate patients’ EQ-5D data into values that can underpin health care allocation and access decisions. The National Institute of Health and Clinical Excellence (NICE), for example, uses TTO values in assessing new technologies.

The objective of this research was to develop a better understanding of the characteristics of the data generated by LT-TTO, improve data collection tools, and provide information for selecting the particular variant of LT-TTO to be used in subsequent research. Now available as OHE Research Paper 10/02, the results of this research already are having an important impact. Research to pilot the use of the methods reported in our paper now is underway in four countries.  An additional four countries will use our results as the basis for further methodological research.  These studies, coordinated by the EuroQol Group, will lay the foundations for future EQ-5D-5L value sets studies.

Background

The estimate of Quality Adjusted Life Years (QALYs) a patient gains from treatment requires that the length of life gained be adjusted by its quality – i.e., the perceived value of life to the patient experiencing a particular health state.  These values (weights) are anchored on a scale where 1 is full health and 0 is dead. Health states perceived to be worse than dead have values of less than 0.

The ‘Time Trade Off’ method is widely used to obtain these values, but it presents some important problems. In particular, the method cannot adequately handle very poor health states that people may consider to be so bad they are ‘worse than being dead’. In such cases, the TTO must switch to a different questioning process to capture value, creating problems for the comparability and interpretation of values less than zero. In previous research,  LT-TTO proved capable of producing weights for states both better and worse than dead.

Aims

The aims of this research were (1) to investigate the values generated from LT-TTO using different combinations of the length of time the individual experiences full health and a particular health state; the order of these states also was varied (Lead v. Lag Time TTO), (2) to gauge whether values generated from these methods concur with participants’ views as to whether the states are better or worse than dead, and (3) to explore a range of methods for handling the preferences of those whose distaste for very poor health states is so great that they are willing ‘use up’ all their lead time to avoid them.

Methods

A sample of 200 members of the general public valued five health states, using two of four variants of the LT-TTO: a lead time of 10 years followed by a health state duration of 20 years; a lead time of 5 years followed by a health state duration of 1 year; a lead time of 5 years followed by a duration of 10 years; and a duration of 5 years of a health state followed by with a lag time of 10 years. Participants also responded to a range of supplementary tasks and other questions.

Results

Values are influenced by the length of the lead time relative to the health state duration. Longer lead times enable somewhat more preferences to be captured, but appear to exert a framing effect on values. Lag time TTO results in both a greater willingness to trade off for mild states of poor health and trading off less time for severe states. Of those who valued the worst health state as less than 0, 70% also expressed the view that this state was worse than dead.

Conclusions

LT-TTO confers an important advantage over TTO by providing a single method capable of generating values greater and less than 0 that seem broadly in keeping with participants’ stated views about those states being better or worse than dead.  However, values are sensitive both to the length of time in full health relative to the duration of the state to be valued and to the order in which these occur (lead vs. lag time). For those who use up their lead time, we show that additional ways of eliciting these preferences (via additional questioning) are feasible, as is modelling those values (via survival analysis). A small (<5%) group of participants remain, however, whose preferences are so ‘extreme’ that they cannot be captured by any approach.

Download Devlin, N et al. (2010) A comparison of alternative variants of the Lead and Lag Time TTO. Research Paper 10/02. London: Office of Health Economics

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Grants

Related News

  • News
  • December 2019

New OHE Research Funding: Improving Labour Productivity in Primary Care

Read more
  • News
  • October 2019

Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase

Read more
  • News
  • May 2019

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Read more
  • News
  • September 2018

UKRI Funds OHE Collaboration in Student Mental Health Research Network

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!